241 results
8-K
EX-99.1
MRK
Merck & Co Inc
25 Apr 24
Merck Announces First-Quarter 2024 Financial Results
6:41am
Phase 2/3 trial evaluating the efficacy and safety of investigational raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer … , as well as plans to conduct clinical trials in both females and males (16-26 years old) to evaluate the efficacy and safety of a single-dose regimen
8-K
EX-99.1
MRK
Merck & Co Inc
26 Oct 23
Merck Announces Third-Quarter 2023 Financial Results
6:38am
PCSK9 Inhibitor Candidate MK-0616
(Read Announcement)
Vaccines
Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL Published
8-K
EX-99.1
8gnop am3t1i8kucwjx
1 Aug 23
Merck Announces Second-Quarter 2023 Financial Results
6:46am
424B5
wu5qs
10 May 23
Prospectus supplement for primary offering
4:27pm
424B5
ub5zycfhmwglm5c2sqlw
8 May 23
Prospectus supplement for primary offering
8:17am
8-K
EX-99.1
ns9d2m 54z
27 Oct 22
Merck Announces Third-Quarter 2022 Financial Results
6:38am
8-K
EX-99.1
fq1 kf6ud
28 Apr 22
Merck Announces First-Quarter 2022 Financial Results
6:35am
8-K
EX-99.1
edvhu7
3 Feb 22
Merck Announces Fourth-Quarter and Full-Year 2021 Financial Results
6:39am
424B5
b1a3ff
9 Dec 21
Prospectus supplement for primary offering
4:37pm